Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2347 - Testing for and frequency of molecular alterations in patients with advanced NSCLC in Germany. Results from the prospective German Registry CRISP (AIO-TRK-0315)


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Pathology/Molecular Biology

Tumour Site


Frank Griesinger


Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292


F. Griesinger1, W.E.E. Eberhardt2, A. Nusch3, M. Reiser4, C. Bernhardt5, N. Marschner6, M. Jaenicke7, A. Fleitz8, L. Spring7, J. Sahlmann9, A. Karatas10, A. Hipper10, W. Weichert11, A. Rittmeyer12, H. Bischoff13, C. Waller14, M. Thomas15

Author affiliations

  • 1 Klinik Für Hämatologie Und Onkologie, Pius Hospital, 26121 - Oldenburg/DE
  • 2 Department Of Medical Oncology, University Hospital Essen Westdeutsches Tumorzentrum, 45122 - Essen/DE
  • 3 Onkologie, Onkologische Praxis Velbert, 42551 - Velbert/DE
  • 4 Onkologie, PIOH (Köln Zentrum) - Praxis Internistischer Onkologie und Hämatologie, 50674 - Köln/DE
  • 5 Onkologie, Gemeinschaftspraxis für Hämatologie und Onkologie, 44263 - Dortmund/DE
  • 6 Medical Oncology, Praxis für Interdisziplinaere Onkologie, 79110 - Freiburg/DE
  • 7 Clinical Epidemiology, iOMEDICO, 79108 - Freiburg/DE
  • 8 Clinical Epidemiology, iOMEDICO AG, 79108 - Freiburg/DE
  • 9 Datamanagement, Statistics And Medical Informatics, iOMEDICO, 79108 - Freiburg/DE
  • 10 Aio Studien Ggmbh, AIO Studien gGmbH, 14057 - Berlin/DE
  • 11 Institute Of Pathology, Technical University of Munich, 81675 - München/DE
  • 12 Lki Lungenfachklinik Immenhausen, LKI Lungenfachklinik Immenhausen, 34376 - Immenhausen/DE
  • 13 Thoraxonkologie, Thoraxklinik Heidelberg, 69126 - Heidelberg/DE
  • 14 Hematology, Oncology And Stem Cell Transplantation, Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, 79106 - Freiburg/DE
  • 15 Thoraxonkologie, Thoraxklinik, Heidelberg/DE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2347


Several therapies targeting molecular alterations in subgroups of NSCLC patients (pts) have been approved and require pts to be tested for these targets. Thorough knowledge of the diagnostic and therapeutic algorithm in routine practice is crucial to evaluate and improve the quality of care.


The prospective, national clinical research platform CRISP recruits pts in currently 149 representative cancer centres in all therapeutic sectors in Germany. Up to 8000 pts will be recruited and followed until death or up to a maximum of 3 years, respectively. Data from 823 pts recruited by 89 centers by June 30th, 2017 was analysed regarding molecular testing. An update with data cut June 30th, 2018 including at least 2.000 pts by 130 centres will be presented at the conference.


Median age was 67 years and 61% of pts were male. 12% of pts were never smokers. 79% of pts had non-squamous carcinoma (nsqc), 21% squamous carcinoma (sqc). Overall 84% (nsqc 92%, sqc 52%) of pts were tested with at least one test method at the start of treatment. Median turn around time was 2 weeks for next generation sequencing (NGS), 10 days for FISH and one week for other sequencing and IHC. In pts with nsqc (n = 653) 32% of pts were tested by NGS, 45% by other sequencing and 49% by IHC and 38% by FISH. Molecular test rates for EGFR, ALK , and ROS-1 were 73%, 70%, and 53% respectively. In pts with sqc (n = 170) 12% of pts were tested by NGS, 11% by other sequencing, 34% by IHC and 10% by FISH. Molecular test rates for EGFR, ALK, and ROS-1 were 23%, 21%, and 15%, respectively. Test rates for PD-L1 increased from 23% in 2016 to 48% in the first half of 2017. For pts with nsqc for whom test results were available at time of analysis, an EGFR alteration was detected in 15% (n = 71), an ALK alteration in 8% (n = 37), and a ROS-1 alteration in 3% (n = 10) of pts. 24% (n = 65) of pts for whom PD-L1 tumour proportion score (TPS) results were available had a TPS ≥50%.


CRISP presents current real life data on molecular testing from all treatment sectors in Germany. Pts are frequently tested for molecular alterations. NGS is used in one third of nsqc pts. Reasons for testing / non-testing and changes over time will be discussed based on the 2018 data cut.

Clinical trial identification


Legal entity responsible for the study



CRISP is supported by AstraZeneca GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol-Myers Squibb GmbH & Co. KGaA, Celgene GmbH, Lilly Deutschland GmbH, MSD SHARP & DOHME GmbH, Novartis Pharma GmbH, Pfizer Pharma GmbH, Roche Pharma AG and Takeda Pharma Vertrieb GmbH & Co.KG.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.